N-benzyl-3-isopropylpyrrolidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-3-isopropylpyrrolidine
• 英文别名: 1-benzyl-3-isopropylpyrrolidine；1-Benzyl-3-propan-2-ylpyrrolidine
• 化学式: C₁₄H₂₁N
• 分子量: 203.327
• InChiKey: WKSZKSJVOTWTTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  氯甲酸苄酯 、 N-benzyl-3-isopropylpyrrolidine 以 甲苯 为溶剂， 反应 2.0h， 生成 benzyl 3-isopropylpyrrolidine-1-carboxylate
  参考文献：
  名称：

  A hydrogen borrowing annulation strategy for the stereocontrolled synthesis of saturated aza-heterocycles

  摘要：

  一种氢借位缩合策略实现了C2、C3和C4取代饱和氮杂环的立体控制合成。

  DOI：

  10.1039/d0cc00903b
• 作为产物：
  描述：

  3-(methoxycarbonyl)-5-methylhexanoic acid 在 lithium aluminium tetrahydride 、 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 cesium bicarbonate 、 环戊基甲醚 作用下， 以 四氢呋喃 为溶剂， 反应 40.5h， 生成 N-benzyl-3-isopropylpyrrolidine
  参考文献：
  名称：

  A hydrogen borrowing annulation strategy for the stereocontrolled synthesis of saturated aza-heterocycles

  摘要：

  一种氢借位缩合策略实现了C2、C3和C4取代饱和氮杂环的立体控制合成。

  DOI：

  10.1039/d0cc00903b

文献信息

• [EN] AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS<br/>[FR] AMINOPYRROLOTRIAZINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019147782A1

  公开（公告）日：2019-08-01

  The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.

  该公开涉及到公式I的化合物，这些化合物可用作激酶调节剂，包括RIPK1调节。该公开还提供了制备和使用这些化合物的方法，例如在涉及坏死或炎症以及其他适应症的治疗中使用。
• NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF
  申请人：VIVOZON, INC.

  公开号：US20140336378A1

  公开（公告）日：2014-11-13

  Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.

  揭示了一种新的苯甲酰胺衍生物及其药用，更具体地说，一种具有化学式1结构或其药用盐的新苯甲酰胺衍生物，以及包括上述材料的用于预防或治疗疼痛或瘙痒的组合物。根据本发明，所述新的苯甲酰胺衍生物及其药用盐表现出优异的镇痛效果，特别是在不仅神经病理动物模型中而且其他模型如福尔马林模型中表现出的镇痛效果，因此，可用于抑制不同类型的疼痛，如伤害性疼痛、慢性疼痛等。此外，由于证明了本发明在瘙痒模型中显示出抗瘙痒功效，应用于疼痛方面建立的机制和治疗概念，因此，本发明还可通过将创新产品应用于抗瘙痒组合物中，以抑制初始瘙痒阶段并治疗其症状，从而预防刮痒阶段后的皮肤损伤或炎症。
• Mono- and Disubstituted N,N-Dialkylcyclopropylamines from Dialkylformamides via Ligand-Exchanged Titanium–Alkene Complexes Part 79 in the series “Cyclopropyl Building Blocks for Organic Synthesis”. For part 78 see: M. Gensini, I. Kozhushkov, S. Yufit, K. Howard, M. Es-Sayed, de Meijere, Eur. J. Org. Chem. 2002, 2499–2507; part 77: H. Nüske, S. Bräse, I. Kozhushkov, M. Noltemeyer, M. Es-Sayed, de Meijere, Chem. Eur. J. 2002, 8, 2350–2369.
  作者：Armin de Meijere、Craig M. Williams、Alexandre Kourdioukov、Sergei V. Sviridov、Vladimir Chaplinski、Markus Kordes、Andrei I. Savchenko、Christian Stratmann、Mathias Noltemeyer

  DOI：10.1002/1521-3765(20020816)8:16<3789::aid-chem3789>3.0.co;2-r

  日期：2002.8.16

  Dibenzylformamide was treated with cyclohexylmagnesium bromide in the presence of either titanium tetraisopropoxide or methyltitanium triisopropoxide and a variety of cyclic and acyclic alkenes and alkadienes to give new mono- and disubstituted as well as bicyclic dialkylcyclopropylamines (Tables 1-3) in yields ranging from 18 to 90 % (in most cases around 55 %). 3-Benzyl-6-(N,N-dibenzylamino)-3-azabicyclo[3

  在四异丙氧基钛或甲基三异丙氧基钛和各种环和无环烯烃与链二烯的存在下，用环己基溴化镁处理二苄基甲酰胺，得到新的单取代和双取代的以及双环的二烷基环丙胺（表1-3），收率范围为18至22。 90％（大多数情况下约为55％）。3-苄基-6-（N，N-二苄氨基）-3-氮杂双环[3.1.0]己烷（10 a）和正交双保护的3-叔丁氧基羰基-6-（N，N-二苄基）-3-氮杂双环[3.1.0]己烷（10 d）以及类似的6-（N，N-二苄氨基）双环[3.1.0]己烷（12）以纯正的非对映异构体形式获得（87、90和90％）。 N-苄基吡咯啉（15a），N-Boc-吡咯啉（15d； Boc ＝叔丁氧羰基）和环戊烯（分别为88％）。1,3-丁二烯（52）和取代的1，3-丁二烯也被氨基环丙烷化得很好，以良好的收率（51-64％）得到2-乙烯基环丙胺。除烯基和芳基取代的化合物外，N，N-二苄基环丙胺可通过催化氢化反应脱苄基成伯环丙胺，如10
• MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES
  申请人：Endres Gregory W.

  公开号：US20100075990A1

  公开（公告）日：2010-03-25

  Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D 2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).

  多杂环芳基化合物，它们的制备，包括这些化合物的药物组合物，以及它们在预防和治疗可能通过抑制造血前列腺素D合成酶（H-PGDS）调节的前列腺素D2介导的疾病和症状中的药用。
• Novel imidazo based heterocycles
  申请人：Calderwood J. David

  公开号：US20070099925A1

  公开（公告）日：2007-05-03

  The present invention is directed to novel imidazopyrazine and imidazopyrimidine compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

  本发明涉及式（I）的新型咪唑吡嗪和咪唑嘧啶化合物，其中变量如在此定义。式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些疾病和病症，特别是炎症性疾病和增殖性疾病和病症，例如癌症。